Dyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Update

Dyne Therapeutics, Inc. (NASDAQ:DYN) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 8,080,000 shares, an increase of 18.5% from the March 15th total of 6,820,000 shares. Approximately 16.2% of the shares of the company are short sold. Based on an average daily volume of 1,710,000 shares, the short-interest ratio is currently 4.7 days.

Dyne Therapeutics Trading Down 1.6 %

NASDAQ DYN opened at $25.44 on Tuesday. The stock has a 50-day simple moving average of $25.85 and a 200 day simple moving average of $16.94. The company has a market capitalization of $2.19 billion, a PE ratio of -6.46 and a beta of 0.95. Dyne Therapeutics has a 12 month low of $6.40 and a 12 month high of $30.27.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.17). As a group, sell-side analysts predict that Dyne Therapeutics will post -3.25 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Jason P. Rhodes sold 248,219 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $23.72, for a total value of $5,887,754.68. Following the sale, the director now owns 903,527 shares of the company’s stock, valued at approximately $21,431,660.44. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Jason P. Rhodes sold 248,219 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $23.72, for a total value of $5,887,754.68. Following the sale, the director now owns 903,527 shares of the company’s stock, valued at approximately $21,431,660.44. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Wildon Farwell sold 5,493 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $25.07, for a total value of $137,709.51. Following the completion of the sale, the insider now directly owns 163,503 shares in the company, valued at approximately $4,099,020.21. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,888,532 shares of company stock worth $44,687,450. Company insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently modified their holdings of DYN. Swiss National Bank increased its holdings in shares of Dyne Therapeutics by 7.6% in the first quarter. Swiss National Bank now owns 54,900 shares of the company’s stock worth $529,000 after acquiring an additional 3,900 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of Dyne Therapeutics by 57.0% in the first quarter. MetLife Investment Management LLC now owns 19,766 shares of the company’s stock worth $191,000 after acquiring an additional 7,180 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Dyne Therapeutics by 39.6% during the first quarter. Dimensional Fund Advisors LP now owns 50,278 shares of the company’s stock worth $484,000 after buying an additional 14,266 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Dyne Therapeutics by 2.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 192,477 shares of the company’s stock worth $1,856,000 after buying an additional 3,918 shares during the period. Finally, UBS Group AG boosted its position in shares of Dyne Therapeutics by 2,368.9% during the first quarter. UBS Group AG now owns 10,172 shares of the company’s stock worth $98,000 after buying an additional 9,760 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on DYN shares. StockNews.com raised Dyne Therapeutics to a “sell” rating in a research note on Thursday, December 21st. Oppenheimer reissued an “outperform” rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, March 26th. Stifel Nicolaus upped their price target on Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Raymond James upped their price target on Dyne Therapeutics from $27.00 to $56.00 and gave the company a “strong-buy” rating in a research note on Thursday, January 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $37.43.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.